title: [Incidence of acute idiopathic optic neuritis and its therapy in Japan. Optic Neuritis Treatment Trial Multicenter Cooperative Research Group (ONMRG)].
abstract: Data on the incidence of and treatment for acute idiopathic optic neuritis were obtained by questionnaire sent to departments of ophthalmology, university hospitals, and general hospitals throughout Japan. Inquiry was made as to the number of cases which developed idiopathic optic neuritis from April 1992 to March 1993 along with their clinical features. The response rate was 53.6%. There were a total of 550 cases, and the male to female ratio was 1:1.22. Patients 14 to 55 years old were 65.9%; bilateral involvement: 28.2%; recurrence: 18.6%; positive past history of the other eye; 7.5%. Assuming the answering rate to be 100% and two thirds of the patients to be included, annual incidence of this disease (the annual number of patients) was determined to be 1.62 for an adult population of 100,000 (1.03 cases/100,000 people). Tochigi, Tokyo, Kanagawa, Hyogo, Wakayama, Okayama, Yamaguchi, Tottori, Shimane, Ehime, and Fukuoka showed an annual incidence exceeding 2.0/100,000 adults. At more than 95% of all medical institutions questioned, patients with optic neuritis were usually treated with systemic corticosteroids. Oral corticosteroid therapy, which was shown in a recent study in USA to be contraindicated, was still being used at 15% of the institutions.
authors.affiliation: Department of Ophthalmology, Kitasato University School of Medicine, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Wakakura
authors.forename: S
authors.initials: S
authors.lastname: Ishikawa
authors.forename: S
authors.initials: S
authors.lastname: Oono
authors.forename: A
authors.initials: A
authors.lastname: Tabuchi
authors.forename: K
authors.initials: K
authors.lastname: Kani
authors.forename: Y
authors.initials: Y
authors.lastname: Tazawa
authors.forename: Y
authors.initials: Y
authors.lastname: Nakao
authors.forename: M
authors.initials: M
authors.lastname: Kiyosawa
authors.forename: K
authors.initials: K
authors.lastname: Kawai
authors.forename: A
authors.initials: A
authors.lastname: Oohira
mesh_terms: D000208:Acute Disease; D000284:Administration, Oral; D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage*; D000328:Adult; D000367:Age Factors; D000075202:Contraindications; D005260:Female; D006801:Humans; D007564:Japan / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D009902:Optic Neuritis / Q000188:drug therapy* / Q000453:epidemiology*; D011239:Prednisolone / Q000008:administration & dosage; D012737:Sex Factors; D011795:Surveys and Questionnaires
chemical_list: D000305:Adrenal Cortex Hormones; D011239:Prednisolone